Pfizer Launches Trial Of Oral Anti-COVID Medication

Reuters reports:

Pfizer Inc has started an early-stage U.S. trial of an oral COVID-19 antiviral therapy that could be prescribed to patients at the first sign of infection, the company said on Tuesday.

The drugmaker said the antiviral candidate showed potent activity against SARS-CoV-2, the virus that causes COVID-19, in lab studies.

Pfizer’s candidate, named PF-07321332, is a protease inhibitor that prevents the virus from replicating in cells. Protease inhibitors have been effective at treating other viral pathogens such as HIV and hepatitis C virus, both on their own and in combination with other antivirals, the company said.

Read the full article.

Pfizer Inc has started an early-stage U.S. trial of an oral COVID-19 antiviral therapy that could be prescribed to patients at the first sign of infection, the company said on Tuesday.​ https://t.co/MKls3nHnGC

— Reuters Health (@Reuters_Health) March 23, 2021